Crumpacker C S
Department of Medicine, Harvard Medical School, Boston, MA.
J Am Acad Dermatol. 1988 Jan;18(1 Pt 2):190-5. doi: 10.1016/s0190-9622(88)70026-2.
The genome of herpes simplex virus codes for several enzymes, including viral thymidine kinase and viral deoxyribonucleic acid (DNA) polymerase. When viral resistance develops, it does so by changes in these two enzymes. Three possible mechanisms of viral resistance to acyclovir include (1) selection of viral mutants that make little or no thymidine kinase and do not phosphorylate acyclovir adequately, (2) selection of mutants that can phosphorylate thymidine but cannot phosphorylate acyclovir (i.e., these viruses have thymidine kinases with altered substrate specificity), and (3) selection of viruses that have altered DNA polymerases that replicate viral DNA in the presence of acyclovir triphosphate. Thymidine kinase-deficient virus has been isolated from clinical isolates frequently, but few strains appear to be virulent for animals or humans and only a few seem to have caused clinical disease. Viruses with altered substrate specificity have been reported but viruses with an altered DNA polymerase have not occurred in clinical practice. Antiviral drugs should be used only when necessary to minimize the appearance of resistant strains of virus.
单纯疱疹病毒的基因组编码多种酶,包括病毒胸苷激酶和病毒脱氧核糖核酸(DNA)聚合酶。当产生病毒耐药性时,是通过这两种酶的变化来实现的。病毒对阿昔洛韦产生耐药性的三种可能机制包括:(1)选择产生很少或不产生胸苷激酶且不能充分磷酸化阿昔洛韦的病毒突变体;(2)选择能够磷酸化胸苷但不能磷酸化阿昔洛韦的突变体(即这些病毒具有底物特异性改变的胸苷激酶);(3)选择在阿昔洛韦三磷酸存在的情况下具有改变的DNA聚合酶从而能够复制病毒DNA的病毒。胸苷激酶缺陷型病毒经常从临床分离株中分离出来,但很少有菌株对动物或人类具有致病性,似乎只有少数导致了临床疾病。已经报道了具有改变的底物特异性的病毒,但具有改变的DNA聚合酶的病毒在临床实践中尚未出现。只有在必要时才应使用抗病毒药物,以尽量减少耐药病毒株的出现。